“The hope for gene editing is that if we do this right, we will only need to do one treatment,” Duke University’s Charlie Gersbach, who led one of three independent research teams that published results in Science last week (December 31), told The New York Times. “This method, if proven safe, could be applied to patients in the foreseeable future.”
The problematic protein is called dystrophin. All three groups took the same approach, first demonstrated in mouse embryos by Eric Olson of the University of Texas Southwestern Medical Center in 2014, to correct dystrophin deficiencies. They clipped a mutant exon from the gene for dystrophin, resulting in a truncated but functional protein. “Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” Olson, whose group was one of the three reporting successful results, said in a press release.
The researchers used viral vectors to deliver their genetic payload to tissues. The third team, led by Harvard University’s Amy Wagers, targeted muscle stem cells and heart muscle cells. The other teams injected the CRISPR-loaded vector into leg muscle or the bloodstream. Each approach succeeded to varying degrees, although as Science pointed out, none of the mice were fully cured. “There’s a ton of room for optimization of these approaches,” Gersbach told Science.